The future of medical congresses

Remember when pharma invested an enormous amount of time, effort and money into attending medical congresses around the world?    In the pandemic-blighted present, where all such global physical events have been put on hold, it seems an age away.    Many organisations – Reuters Events Pharma and ASCO to name but two - took immediate action and successfully transitioned their events to a digital format in record time; others were more risk-averse and chose to postpone events pending more certainty.  So whither medical congresses now? Christoph Schmidt, former global head of commercial excellence at Actelion Pharmaceuticals believes the pandemic accelerated a trend that was already moving towards a more digitally mature set-up.    He predicts that the days of mega congresses, where upwards of 100,000 physicians would travel from all over the world to congregate in a single venue, are over. “In the future such events will be on a much smaller scale with broadcasts over social media and information sharing through different channels,” says Schmidt.  He points to research that shows the information-seeking preferences of healthcare professionals have changed over the years. Many now demanding content in a format, on a channel and at a time that is convenient to them. Jessica Federer, former chief digital officer at Bayer, agrees: “The trend was already moving away from having so many people come to...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Australian lawmakers took to Twitter to school American critics of the country’s COVID-19 public health measures, pointing to how well they have worked to prevent deaths in comparison to policies in the U.S., where the death toll has been one of the worst in the world. Since the pandemic began, Australia has enforced strict measures to prevent the spread of COVID-19, including some of the world’s longest lockdowns. State and territory-wide restrictions can only be lifted once more than 80% of the local population aged 16 and older is fully inoculated against the virus. In the U.S., by comparison, many states l...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Australia COVID-19 overnight Second click uspoliticspolicy Source Type: news
This article addresses the current debates over COVID-19 antivirals and vaccine boosters and takes other considerations into account: Whether the widespread use of antivirals will be possible and advisable What might happen if long-term efficacy of the vaccine is shown to be low, and how do we develop therapeutics to address the unmet need Why there are not enough new marketed therapeutics What we have learned from research so far and from other pandemics Since the beginning of the COVID-19 pandemic, the scientific community and the media have been debating over different items which have changed with time, including...
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
The definition of Long COVID has varied throughout the pandemic. The World Health Organisation (WHO) has just produced a 2 External 0 0 0new definition of Long COVID false https://apps.who.int/iris/bitstream/handle/10665/345824/WHO-2019-nCoV-Post-COVID-19-condition-Clinical-case-definition-2021.1-eng.pdf true false%>, which they call'post COVID-19 condition'. They describe it as a syndrome that occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually three months from the onset of COVID-19 with symptoms that last for at least two months and cannot be explained by an alternative diagnos...
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
Source: New Scientist - Health - Category: Consumer Health News Source Type: research
Novant Health continues to be at the forefront of care in the ongoing COVID-19 pandemic, administering over half a million doses of the vaccine.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: news
.
Source: Human Vaccines and Immunotherapeutics - Category: Allergy & Immunology Authors: Source Type: research
a Mores Andrea Cambieri Giuseppe Vetrugno Gianfranco Damiani Patrizia Laurenti Health workers, especially those in patient-facing roles, had a significantly increased risk of COVID-19 infection, having serious outcomes, and risking spreading the virus to patients and staff. Vaccination campaign planning suggests allocating initial supplies of BNT162b2 vaccine to health workers given the importance of early protection to safeguard the continuity of care to patients. The aim of the study is to assess the effectiveness and safety of BNT162b2 vaccine among the health workers of Fondazione Policlinico Universitario ...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, challenging both the medical and scientific community for the development of novel vaccines and a greater understanding of the effects of the SARS-CoV-2 virus. COVID-19 has been associated with a pronounced and out-of-control inflammatory response. Studies have sought to understand the effects of inflammatory response markers to prognosticate the disease. Herein, we aimed to review the evidence of 11 groups of systemic inflammatory markers for risk-stratifying patients and prognosticating outcomes related to COVID-19. Numerous studies have demonstrated ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
NEW BRUNSWICK, N.J., October 21, 2021 – Johnson &Johnson (the Company) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine. “Today’s recommendation supports the use of the Johnson &Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention (CDC), authorized booster doses of COVID-19 vaccines for certain groups. Walensky followed the advice of a CDC expert panel, which recommended the boosters in in two unanimous votes earlier in the day. The 15-member Advisory Committee on Immunization Practices (ACIP) advised that anyone who was initially vaccinated with the Moderna shot get a booster at least six months later, and that J&J-Janssen recipients receive a booster at least two months after their initial vaccination. The endorsement follows a similar decision from the Food and Drug...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Cancer & Oncology | Computers | Conferences | COVID-19 | Education | Environmental Health | Learning | Marketing | Men | Organic | Pandemics | Partnerships | Pharmaceuticals | Politics | Universities & Medical Training | Vaccines | Women